The pharmaceutical company, questioned by an investigation by the Financial Markets Authority, presented on Saturday a summary of the public meeting of Friday February 11 organized by the Sanctions Commission of the said authority. During the session, AB Science once again strongly opposed the grievances of the AMF.
The title AB Science fell by more than 9% this morning, following the public meeting organized by the Sanctions Commission of the Financial Markets Authority on February 11. This session is part of the survey started in September 2017 relating to financial information and the AB Science stock market.
As a reminder, the Autorité had notified the pharmaceutical company of the following grievance: firstly, ” not having communicated to the market in due time information that it considers privileged relating to the marketing authorization procedure for masitinib in mastocytosis from March 7, 2017 “. Said authority had also implicated Alain Moussy, Chairman and CEO and founder of AB Science, and accused him of having ” used this privileged information to sell part of its shares and requested financial sanctions “.
During the session, AB Science and Alain Moussy opposed these grievances and remain confident ” in the arguments submitted to the Sanctions Committee “. The Committee Rapporteur, for her part, “ considered that such privileged information did not exist during the fundraising carried out by AB Science on March 24 and 27, 2017 and during the sale carried out by Alain Moussy on March 31, 2017 “.
Result in four to six weeks when the Commission’s decision is announced.
THE